Antidepressant Treatment in Major Depressive Disorder (MDD) – 16 de mayo


I am delighted to invite you to take part in this international Masterclass webinar on Major Depressive Disorder (MDD), which is organised and sponsored by H. Lundbeck A/S. This promotional webinar will be held online on 16 May 2023 and will cover a broad range of topics highly relevant to your clinical practice.

The focus of this Masterclass webinar is Challenges in the management of MDD: The complexity of comorbidity. This session will consider a selection of common somatic and psychiatric comorbidities that healthcare professionals frequently face when treating patients with MDD. We will not just discuss the added impact of comorbidities to the MDD disease course, but also how comorbidities can impact treatment considerations for the clinical management of MDD. We will highlight some of the newest data from studies involving MDD and a range of comorbidities and feature some of the latest clinical data on vortioxetine* in these contexts.

This interactive Masterclass webinar will include an engaging mix of plenary presentations, lively panel discussions, and multiple Q&A opportunities with our international faculty. You will have ample opportunity to hear expert perspectives on common comorbidities encountered during the treatment of MDD. We hope that attending this webinar will broaden your knowledge in this area and provide useful new insights to support your clinical practice and share with your colleagues.



3 min
Welcome & introductions
Mohammad Alsuwaidan
10 min
Complexities in the clinical management of patients with MDD and comorbidities*
Mohammad Alsuwaidan
10 min
Panel discussion: What are the greatest challenges you face in clinical management of patients with MDD and comorbidities?
Followed by Q&A | All speakers
10 min
How do somatic comorbidities influence the management of MDD?*
Susana Almeida
15 min
How can we best manage MDD in older patients with comorbidities?*
Zahinoor Ismail
10 min
Q&A
All speakers
5 min
MDD with comorbid substance abuse disorder: What are the key treatment considerations?*
Mohammad Alsuwaidan
5 min
MDD and COVID-19: What do we know now?*
Mohammad Alsuwaidan
10 min
MDD with anxiety: How can we improve outcomes for patients with a more severe course of MDD?*
Susana Almeida
10 min
Panel discussion: How do comorbidities in patients with MDD influence your treatment decisions?
Followed by Q&A | All speakers
2 min
Summary & close
Mohammad Alsuwaidan

*Presentations will include data on vortioxetine


Dr. Mohammad Alsuwaidan
Kuwait City, Kuwait

Dr. Susana Almeida
Porto, Portugal

Dr. Zahinoor Ismail
Calgary, Canada